UPDATE Citi Lowers Price Target on Incyte to $15

According to Citi, Incyte

price target is lowered to $15. Citi said that it conducted a 25-physician survey in Nov. 2011 on the potential clinical adoption of Jakafi (ruxolitinib) in anticipation of the FDA approval. “On average, physicians expect to prescribe Jakafi in ~35% of their overall MF patients.” Incyte closed on Friday at $14.24.